A
ADIAL PHARMACEUTICALS, INC.
ADILCIK 0001513525NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-7.98M
Total Assets
$6.67M
Equity
$5.28M
Shares Out
1.43M
Op. Cash Flow
$-6.49M
Business
ADIAL PHARMACEUTICALS, INC. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment or prevention of addiction and related disorders. Its main offering is AD04, an investigational ondansetron-based drug candidate for alcohol use disorder, paired with a companion genetic diagnostic to identify responsive patients. The company’s activities center on clinical development, regulatory interactions, intellectual property licensing and diagnostic integration focused on genotype-defined subgroups. ADIAL targets the U.S. regulatory pathway while also engaging European/UK regulators and international clinical sites.
Summary from filing dated 2025-03-04
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2025 2025-09-30 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 3 | — | 3 | 1 | 2 | |
| General and administrative | 5 | — | 5 | 6 | 9 | |
| Total Operating Expenses | 8 | — | 8 | 7 | 11 | |
| Loss From Operations | −8 | — | −8 | −7 | −11 | |
| Interest income | 149,567 | — | 178,659 | 69,779 | 63,338 | |
| Inducement expense | — | — | −4 | — | — | |
| Loss on equity method investment | −492,130 | 492,130 | −552,183 | −193,884 | — | |
| Other income (expense) | 164,854 | — | −75,043 | 10,162 | — | |
| Total other Income (Expense) | −177,709 | — | −5 | −113,943 | 63,338 | |
| Net Loss | −8 | — | −13 | −5 | −13 | |
| Loss per share, basic (in Dollars per share) | −11.93 | — | −68.01 | −3.6 | −12.71 | |
| Loss per share, diluted (in Dollars per share) | −11.93 | — | −68.01 | −3.6 | −12.71 | |
| Weighted average shares, basic (in Shares) | 668,630 | — | 194,059 | — | 25 | |
| Weighted average shares, diluted (in Shares) | 668,630 | — | 194,059 | 1 | 1 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 6 | 4 | 3 | 4 | 6 | |
| Prepaid expenses and other current assets | 299,666 | 308,239 | 371,597 | 349,441 | 389,501 | |
| Total Current Assets | 6 | 4 | 3 | 5 | 6 | |
| Intangible assets, net | 2,784 | 3,348 | 3,913 | — | — | |
| Equity method investment | 489,700 | 981,830 | 2 | — | — | |
| Total Assets | 7 | 5 | 5 | 6 | 7 | |
| Accounts payable | 655,207 | 250,130 | 103,325 | 276,410 | 286,192 | |
| Accrued expenses | 741,702 | 677,456 | 477,747 | 963,327 | 2 | |
| Total Current Liabilities | 1 | 975,858 | 653,076 | 2 | 3 | |
| Total Liabilities | 1 | 975,858 | 653,076 | 2 | 4 | |
| Commitments and contingencies see Note 8 | — | — | — | — | — | |
| Preferred Stock, 5,000,000 shares authorized with a par value of $0.001 per share, 0 shares outstanding at December 31, 2025 and 2024 | — | — | — | — | — | |
| Common Stock, 100,000,000 shares authorized with a par value of $0.001 per share, 1,111,124 and 258,940 shares issued and outstanding at December 31, 2025 and 2024, respectively | 1,111 | 259 | 1,663 | 1,067 | 20,947 | |
| Additional paid in capital | 95 | 86 | 73 | 67 | 54 | |
| Accumulated deficit | −90 | −82 | −69 | −64 | −51 | |
| Total Stockholders Equity | 5 | 4 | 4 | 3 | 4 | |
| Total Liabilities and Stockholders Equity | 7 | 5 | 5 | 6 | 7 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 676,200 | 796,831 | 2 | 3 | 4 | |
| Amortization of intangible assets | 565 | 565 | 564 | 564 | 565 | |
| Cost of commitment shares issued | — | 74,999 | 51,901 | — | — | |
| Change in fair value contingent consideration | −150,000 | — | — | — | — | |
| Prepaid expenses and other current assets | 8,572 | 63,358 | −22,156 | 40,060 | 112,188 | |
| Accrued expenses | 100,296 | 199,709 | −485,580 | −1 | 2 | |
| Accrued expenses, related party | — | −47,942 | — | — | — | |
| Accounts payable and other current liabilities | 405,077 | 146,805 | −183,473 | — | — | |
| Accounts payable, related party | −48,272 | 24,210 | — | — | — | |
| Net cash used in operating activities | −6 | −7 | −7 | −11 | −12 | |
| Cash receipt from contingent consideration | 150,000 | — | — | — | — | |
| Net cash provided by investing activities | 150,000 | — | 2 | — | −34,016 | |
| Net proceeds from sale of common stock | 4 | 4 | 749,943 | 9 | 12 | |
| Proceeds from warrant exercise, net of expenses | 5 | 4 | 503 | 1,865 | 1 | |
| Net cash provided by financing activities | 8 | 8 | 4 | 9 | 14 | |
| NET INCREASE IN CASH AND CASH EQUIVALENTS | 2 | 923,443 | −1 | −2 | 2 | |
| Issuance of common stock to settle bonus accrual | 36,050 | — | — | — | 1 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro